Roivant Sciences Ltd. bought $350M of IMVT
director, owner at Immunovant, Inc.. 16,666,666 shares at an average of $21.00, traded Dec 12, 2025, filed Dec 12, 2025.
Score components
- +15RoleDirector
- +25Trade size$350.0M at market
- +3Relative to holdingsHoldings up 17%
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.5%, 3m -7.6%, 6m +27.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-25-045409, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2025 | POpen-market purchase Common Stock, $0.0001 par value per share | +16,666,666 | $21.00 | $350M | 113,317,007 | Dec 12, 2025 |
Related signals
Other insiders at Immunovant, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $72k 2,241 shares | -1% | |
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $122k 3,809 shares | -2% | |
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $43k 1,327 shares | -1% | |
| 35Weak | Immunovant, Inc. | Eric Venker Chief Executive Officer | $120k 3,506 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $103k 2,846 shares | -2% | |
| 0Weak | Immunovant, Inc. | Atul Pande director | $65k 1,500 shares | -1% | |
| 39Weak | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $135k 3,056 shares | -1% | |
| 50Moderate | Immunovant, Inc. | Tiago Girao Chief Financial Officer | $263k 6,798 shares | -3% | |
| 2Weak | Immunovant, Inc. | Atul Pande director | $60k 1,500 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $111k 2,857 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.